AstraZeneca, Safety Assessment, Södertälje, Sweden.
J Pharm Sci. 2013 Mar;102(3):1116-24. doi: 10.1002/jps.23447. Epub 2013 Jan 11.
Avoiding unwanted immunogenicity is of key importance in the development of therapeutic drug proteins. Animal models are of less predictive value because most of the drug proteins are recognized as foreign proteins. However, different methods have been developed to obtain immunotolerant animal models. So far, the immunotolerant animal models have been developed to assess one protein at a time and are not suitable for the assessment of combination products. Our aim was to develop an animal model for evaluating the impact of manufacturing and formulation changes on immunogenicity, suitable for both single protein and combination products. We constructed two lines of transgenic mice expressing the three human coagulation factors, II, VII, and X, by inserting a single vector containing the three coagulation factors encoding sequences separated by insulator sequences derived from the chicken beta-globin locus into the mouse genome. Immunization of transgenic mice from the two lines and their wild-type littermates showed that transgenic mice from both lines were immunotolerant to the expressed human coagulation factors. We conclude that transgenic mice immunotolerant to multiple proteins can be obtained, and that these mice are potentially useful as animal models in the assessment of immunogenicity in response to manufacturing changes.
避免不必要的免疫原性是治疗性药物蛋白开发的关键。由于大多数药物蛋白被认为是外来蛋白,动物模型的预测价值较低。然而,已经开发出不同的方法来获得免疫耐受动物模型。到目前为止,免疫耐受动物模型已经开发出来,用于评估一种蛋白质,而不适合评估组合产品。我们的目的是开发一种动物模型,用于评估制造和配方变化对免疫原性的影响,适用于单一蛋白和组合产品。我们通过将包含三个凝血因子编码序列的单个载体插入到小鼠基因组中,构建了两条表达三种人凝血因子 II、VII 和 X 的转基因小鼠品系,该载体由来自鸡β-珠蛋白基因座的绝缘子序列分隔。来自这两条线的转基因小鼠及其野生型同窝仔鼠的免疫接种表明,这两条线的转基因小鼠对表达的人凝血因子具有免疫耐受性。我们得出结论,能够获得对多种蛋白质具有免疫耐受性的转基因小鼠,并且这些小鼠可能作为评估制造变化引起的免疫原性的动物模型有用。